Expert InterviewMAZE
Slingshot members are talking to an expert! The topic is:
A Second Opinion: Reviewing Maze Therapeutics' Topline Data from the Phase 2 HORIZON Trial of MZE829 in Patients with Broad APOL1-Mediated Kidney Disease
Executed on:Apr 14, 2026 1:00 PM EDT
Call Duration:30 minutes
Expert Profile
ExpertBlinded Expert
Institution: Mass General | Harvard
- Clinical researcher & clinician in academic nephrology practice; Nephrologist at Massachusetts General Hospital and Instructor in Medicine at Harvard Medical School.
- Currently manages 30+ patients each for IgAN and FSGS
- Conducts patient-oriented research in the areas of calciphylaxis, vascular calcification and hyponatremia, has authored over 50 peer-reviewed research articles, and research is funded by organizations including the American Kidney Fund & the National Kidney Foundation.
Interview Goal
The goal of this interview with a nephrologist is to discuss the Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease and its potential fit within the current treatment landscape.